Immix Biopharma IMMX Institutional Ownership

Immix Biopharma, Inc. (NASDAQ:IMMX) showed up in the 13F filings of 111 institutional investors as of June 2026.

• Collectively, these holders controlled 88.4% of Immix Biopharma's outstanding shares in June 2026, up from 57.6% in March 2026.
• They increased total shares held in Immix Biopharma by 156.58% from the prior quarter, while the number of investors in IMMX increased 382.61% year over year.
• Of these 111 funds, 82 grew their exposure to Immix Biopharma, 13 cut back, and 16 maintained positions.
• In total, institutional investors held 56.35Mn shares in Immix Biopharma as of June 2026, up by 34.39Mn shares quarter on quarter, and up 54.2Mn shares year over year.
• Jupiter Topco LLC is the top holder of Immix Biopharma as of June 30, 2026, with 9.78Mn shares representing 15.34% of outstanding stock.
• Top purchasers of IMMX stock for the quarter ending June 2026 included Jupiter Topco LLC (9.78Mn), State Street Corp (2.81Mn), Deep Track Capital, LP (2.78Mn), BlackRock, Inc. (2.52Mn), Opaleye Management Inc. (2.34Mn).
• Top sellers of IMMX stock for the quarter ending June 2026 included SUSQUEHANNA INTERNATIONAL GROUP, LLP (432.66K), Logos Global Management LP (225.0K), Blue Owl Capital Holdings LP (110.0K), Sei Investments Co (79.79K), Qube Research & Technologies Ltd (45.71K).
• According to Business Quant data, leading holders of IMMX for June 2026 are Jupiter Topco LLC (9.78Mn), Saturn V Capital Management LP (4.66Mn), EVENTIDE ASSET MANAGEMENT, LLC (3.89Mn), State Street Corp (3.0Mn), BlackRock, Inc. (2.99Mn), Deep Track Capital, LP (2.78Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.51Mn), Opaleye Management Inc. (2.34Mn), MILLENNIUM MANAGEMENT LLC (2.07Mn), UBS Group AG (1.94Mn).